Comparative Pharmacology
Head-to-head clinical analysis: DYRENIUM versus TRIAMTERENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYRENIUM versus TRIAMTERENE.
DYRENIUM vs TRIAMTERENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium-sparing diuretic; competitively inhibits sodium reabsorption in the distal renal tubule, reducing sodium-potassium exchange and increasing sodium and chloride excretion while retaining potassium.
Triamterene is a potassium-sparing diuretic that inhibits epithelial sodium channels (ENaC) in the distal convoluted tubule and collecting duct of the nephron, reducing sodium reabsorption and potassium excretion.
Oral: 100 mg twice daily. Maximum: 300 mg/day.
100-300 mg orally once daily; maximum 300 mg/day.
None Documented
None Documented
Terminal elimination half-life approximately 24-72 hours (average 48 hours), prolonged in renal impairment; clinical context: supports once-daily dosing, but accumulation may occur with repeated dosing.
Clinical Note
moderateTriamterene + Digoxin
"The therapeutic efficacy of Digoxin can be decreased when used in combination with Triamterene."
Clinical Note
moderateTriamterene + Digitoxin
"The therapeutic efficacy of Digitoxin can be decreased when used in combination with Triamterene."
Clinical Note
moderateTriamterene + Deslanoside
"The therapeutic efficacy of Deslanoside can be decreased when used in combination with Triamterene."
Clinical Note
moderateTriamterene + Acetyldigitoxin
Terminal elimination half-life is approximately 1.5 to 2 hours. However, in patients with hepatic cirrhosis, half-life may be prolonged up to 4 hours; in renal impairment, half-life can extend significantly (up to 10 hours) due to reduced renal clearance.
Primarily renal (hepatic metabolism to active metabolites, then renal excretion); approximately 50% of the dose is excreted unchanged in urine; minor biliary/fecal elimination.
Approximately 50% of an oral dose is excreted unchanged in urine; about 20% is excreted as metabolites (mainly hydroxytriamterene sulfate conjugate) in urine; biliary/fecal excretion accounts for less than 10%.
Category C
Category A/B
Potassium-Sparing Diuretic
Potassium-Sparing Diuretic
"The therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Triamterene."